---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-091094"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2023-11-29T23:59:59+00:00"
generated_at: "2026-06-07T20:16:41.911906+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adial Pharmaceuticals regains compliance with Nasdaq stockholders' equity minimum

## Summary
- Regained compliance with Nasdaq Listing Rule 5550(b)(1) requiring at least $2.5M stockholders' equity.
- Nasdaq will monitor compliance; failure to show compliance in next periodic report could lead to delisting.
- Company issued press release on November 29, 2023 announcing the compliance notice.

## SEC filing metadata
- accession: 0001213900-23-091094
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2023-11-29T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390023091094/0001213900-23-091094-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390023091094/ea189246-8k_adialpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-091094
- JSON: https://secwatch.observer/filing/0001213900-23-091094.json
- Plain text: https://secwatch.observer/filing/0001213900-23-091094.txt

## Key facts
- Listing & Compliance Notices
  ADIAL PHARMACEUTICALS, INC. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: compliance regained
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: November 29, 2023, Adial Pharmaceuticals, Inc. (the “Company”), received a letter (the “Notification Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that based on the Current Report on Form 8-K that the Company filed with the Securities and Exchange Commission on November 28, 2023 it determined that the Company was in compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”). The letter further stated that if the Company fails to evidence compliance with the Rule upon filing its next periodic report it may be subject to delisting. At that time, Nasdaq staff will provide written noti
  evidence_url: https://www.sec.gov/Archives/edgar/data/1513525/000121390023091094/0001213900-23-091094-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.